Meissa Vaccines is focused on developing innovative live attenuated vaccines to combat life-threatening respiratory viruses, including respiratory syncytial virus (RSV) and SARS-CoV-2 (COVID-19). Central to their approach is the proprietary AttenuBlock platform, which utilizes synthetic biology techniques to enhance vaccine efficacy. This platform allows for the precise modification of viral genomes through codon deoptimization, which reduces the efficiency of viral protein translation while maintaining the virus's ability to stimulate a robust immune response. By optimizing antigen expression and minimizing immune suppressor gene activity, Meissa aims to create vaccines that not only provide strong immunity but also ensure safety and stability.

The company’s vaccine candidates are designed for intranasal delivery, offering a needle-free and adjuvant-free option that targets both systemic and mucosal immunity. This method is particularly advantageous for respiratory viruses, as it generates both serum IgG and mucosal IgA antibodies, which are crucial for blocking infection and transmission. Meissa's commitment to scalable and economical manufacturing processes further supports their goal of delivering effective vaccines globally. Their ongoing clinical trials and positive interim data underscore the potential of their AttenuBlock platform to address significant public health challenges posed by respiratory viruses.

United States

Meissa is a private biotech company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert, co-founded Meissa. They are supported by a team with extensive experience in all aspects of vaccine development. Meissa is currently a resident company at the Johnson & Johnson Innovation – JLABS in South San Francisco.

Meissa Vaccines

Company Details